Summary

  • LifeVac’s donations and state stocking laws have placed the company’s suction-based anti-choking device in more than 10,000 U.S. schools, while the American Heart Association and American Red Cross have declined to include the device in their choking guidelines, citing insufficient evidence.
  • The Food and Drug Administration authorized LifeVac in March as a second-line tool to be used only after the Heimlich maneuver and back blows have failed, after warning the company four times in 2025 to stop distributing the device prior to that authorization.
  • New York City conditioned implementation of its stocking law on medical-guideline endorsement, exposing the split between state mandates and clinical-guideline processes to jurisdiction-by-jurisdiction variation.
  • The death of eight-year-old Nicholas Gray in February, in which school staff and emergency responders attempted the Heimlich, a LifeVac device, a defibrillator, and CPR in sequence, illustrates the timing question the FDA warning explicitly identifies.
  • Independent reviewers, including Dr. Cody Dunne of the University of Calgary, characterize published research on anti-choking devices as case reports, mannequin studies, and cadaver studies, none of which directly simulate a live human choking.

LifeVac, the sole suction-based anti-choking device authorized by the Food and Drug Administration, has placed more than 10,000 units in U.S. schools through donations and through stocking mandates in Texas, New York City, and at least nine other states weighing similar legislation, according to a Wall Street Journal report published Wednesday. The American Heart Association and American Red Cross, which set the first-aid guidelines that school nurses and emergency responders follow, do not include the device in their choking protocols, telling the Journal the published evidence base is too limited to support a recommendation. The gap between federal clearance and clinical-guideline endorsement — and the FDA’s own warning that “using an anti-choking device before established protocols could delay critical life-saving action” — frames the policy question now facing state legislatures, school districts, and the families whose children attend the campuses where the devices are being installed.

The regulatory-versus-guideline split

The FDA authorized LifeVac in March as a second-line treatment for adults and children over 1 year old, “to be used only after the Heimlich maneuver and back blows have failed.” The agency’s authorization is the first signal on which state legislatures have acted; the clinical guidelines issued by the AHA and the Red Cross are the second signal, and the two systems are not synchronized.

Dr. Benny Joyner, a pediatrician and co-chair of the AHA’s pediatric basic life-support guidelines, told the Journal that “it might work, but we don’t know,” and that studies on the devices are “too limited to base a recommendation on them.” The American Red Cross said that while its scientific advisory council once discussed a potential recommendation, its guidance remains unchanged and anti-choking devices are not included in its courses or training programs. The FDA’s own authorization materials warned that “using an anti-choking device before established protocols could delay critical life-saving action,” and some emergency-response experts have expressed concern that “people will waste precious minutes grabbing an anti-choking device when they should be performing back blows, abdominal thrusts or CPR.” A person who is choking can lose consciousness and go into cardiac arrest within three to five minutes, the Journal reported — a window the difference between first-line and second-line action does not survive once lost.

The regulatory pathway also carries a documented compliance history. The FDA warned the company four times in 2025 to stop marketing and distributing its device prior to authorization, and then pointed out that the company had not complied with those requests. When the agency authorized the device in March, it required LifeVac to conduct a post-market study collecting “data on device use, including adverse events, and further performance testing to show it works as intended.” That study is the mechanism by which the regulatory and clinical-guideline tracks could converge over the medium term.

Legislative and commercial trajectory

Texas enacted a law last year requiring school districts to stock at least one anti-choking device on each campus with at least one employee trained to use it. New York City passed a similar law. At least nine other states have weighed or are weighing comparable bills. New Jersey state Sen. Kristin Corrado, who co-sponsored one of the bills, told the Journal: “It’s a priority. If we have the opportunity to save a life, we have to use all means available.”

LifeVac has donated more than 10,000 devices to schools across the country, the Journal reported. The company sells a four-device school kit that retails for nearly $280, with a 20 percent discount for schools. CEO Arthur Lih told the Journal he expects the company to bring in $70 million in revenue globally this year.

The legislative pattern is not uniform. New York City said it would not implement its law unless the devices are recommended in medical guidelines. State health departments, emergency responders, and teachers unions have pushed back against proposals to require the devices in schools because medical guidelines have not endorsed them. The combination — mandates in some jurisdictions, conditional implementation in another, pushback from professional bodies elsewhere — produces a state-by-state patchwork rather than a single national trajectory.

The Nicholas Gray incident

Eight-year-old Nicholas Gray died in February after choking on a grape at school in Manvel, Texas. School staff, including a nurse, and emergency responders tried multiple techniques, including the Heimlich maneuver and a LifeVac device, as well as a defibrillator and CPR, according to his mother Kenzie Gray and reports of the incident reviewed by the Journal.

Kenzie Gray told the Journal: “It was a very expensive price for me to pay in that my child is now in heaven.” She told the Journal she believes teachers need hands-on training in the traditional techniques to rescue people from choking. In-person training became mandatory at the school only after her son’s death, she said.

The documented rescue sequence — staff and emergency responders attempting multiple interventions in sequence, with the device applied in the same incident window as the first-line techniques — raises the sequence-and-timing question that the FDA warning explicitly addresses and is consistent with the FDA-warning dynamic of first-line action potentially delayed. The Gray incident is the leading signal that will likely be examined against any subsequent LifeVac deployment, particularly in school settings where the same rescuer population — teachers, nurses, staff — may face the same window.

Independent evidence assessment

Dr. Cody Dunne, an emergency medicine physician and Ph.D. candidate at the University of Calgary who led one of the studies cited by LifeVac and has not taken funding from the company, told the Journal: “Initial data is promising and there may be a role, but we just don’t have the clear data to tell us exactly where that role is.” Dunne characterized published research on anti-choking devices as based on “case reports, mannequin studies and cadaver studies, none of which directly simulate a live human choking.” Most important, Dunne said, “would be to make sure that every single teacher, every high-school student, every principal, every janitor knows basic CPR and basic life support because that’s the first line, and there’s no sense having the second-line therapy if everyone’s not comfortable doing the first line.”

The LifeVac database the company submitted to the FDA showed 961 cases of complete or partial success, 87 percent of the uses analyzed from the company’s database. The same summary showed 53 serious adverse events related to choking from 2016 through 2025, including 15 deaths. The company said none of the deaths were related to its device; the FDA said the deaths do not establish that the device caused or contributed to them. Lih told the Journal scientific evidence — including 22 independent studies — shows the device is safe and effective.

The reported 87 percent success rate is drawn from the company’s own database; the AHA’s evidentiary threshold for guideline inclusion has not yet been met on independent controlled data. The reported success rate coexists with limited controlled evidence, and the two metrics stand on different methodological footing.

Marketing and pre-authorization conduct

Lih told the Journal: “If someone’s choking, try and get them to cough, do the Heimlich, back blows, do it, do it, do it, do it. If it doesn’t work, you got a backup.” Lih said: “We are promoting the heck out of the Heimlich. Everything we say is, use it after protocol.” Lih said the device also offers a rescue option for people with disabilities or other conditions like obesity or pregnancy that make established methods “impossible or impractical.” Lih told the Journal that inspiration for his design came from a sink plunger from Home Depot and suction devices in ambulances.

According to the Journal, LifeVac promotes the device to police departments, families, and as a baby-shower gift in social-media ads and through a national spokesperson — former Secretary of Housing and Urban Development Ben Carson, a retired pediatric neurosurgeon. Lih said the company has reports of more than 6,500 lives saved with its device overall, and the device has been used to resolve 120 choking incidents in schools.

Phil Heimlich, a former prosecutor and former county commissioner in Cincinnati and the son of Dr. Henry Heimlich, told the Journal: “There’s massive amounts of money going to promote these devices. If they were serious about informing people about how to save lives, they would put the Heimlich maneuver on top of their website.”

LifeVac’s marketing conduct and the legislative activity are not documented as coordinated, but the simultaneity is on the record: the company’s marketing reach, the legislative push, and the device donations are operating in the same window, with the FDA’s pre-authorization warnings part of the same timeline.

Consequences and sequel across horizons

The leading signal of which trajectory is unfolding would likely be the next documented school choking incident involving a LifeVac device — specifically whether the device appears in the rescue sequence as applied only after established methods have failed, or as an early intervention that delays them.

Immediate window: dampening factors include New York City’s conditional implementation stance, documented pushback from state health departments, emergency responders, and teachers unions in other states, and the FDA-required post-market study itself. Reinforcing factors include legislative momentum in at least nine additional states and LifeVac’s 10,000-unit donation program.

Short term — months to a year: the FDA-required post-market study collects data on device use, adverse events, and further performance testing; results arrive within the planning horizon and can move the AHA/Red Cross guideline review in either direction. At the same time, the device-installed base can expand before guidelines are updated.

Medium term — one to five years: the regulatory-versus-guideline split creates exposure to litigation in which plaintiffs’ attorneys in choking-incident cases examine whether a school followed AHA/Red Cross guidance or substituted a non-endorsed device for the endorsed sequence. School liability carriers will encounter the same question. The AHA and Red Cross can update their guidelines as evidence accumulates; the FDA can modify or withdraw the authorization based on post-market data. New York City’s conditional implementation preserves a state-level off-ramp but does not resolve the question for jurisdictions that have moved ahead.

Longer horizon: the gap may narrow as post-market data accumulates, or it may widen if state mandates continue to outpace the guideline process. Whether the medium-horizon scenario produces convergence depends on whether the FDA-required study’s methodology produces evidence the AHA and Red Cross treat as meeting their evidentiary threshold for guideline inclusion.

Vulnerabilities visible to outside parties

The marketing-versus-labeling gap is one exposure. The FDA cleared LifeVac as a second-line device; Lih told the Journal that “everything we say is, use it after protocol.” Phil Heimlich’s public observation is that in marketing the second-line status is not prominently featured. Under stress, responder decisions track what is salient; if the second-line status is not salient, the FDA’s intended sequence is at risk of being inverted in practice. A corrective conditioned on Phil Heimlich’s critique — making the second-line status appear with the prominence he says it currently lacks, as a condition of continued authorization — would address the sequence-protection concern the FDA warning articulates.

The verification gap on the lives-saved metric is another. The 6,500-lives-saved figure and the 120-school-incidents figure are self-reported and not adjudicated against an independent registry. The 87 percent success figure is drawn from the company’s own database. An adversarial reviewer can argue the figures overstate effectiveness, a sympathetic reviewer that they understate it. Either way, the figure functions as marketing copy rather than clinical evidence. An independent adverse-event registry would address the gap Dunne identified between self-reported effectiveness and verified evidence.

The pre-authorization compliance history is on the record. The FDA warned the company four times in 2025 to stop marketing and distributing its device prior to authorization, and then pointed out that the company had not complied with those requests. For any subsequent reviewer of the authorization’s terms, that pattern is part of the device’s record. A corrective that makes compliance history a documented criterion in any future authorization review would address that record’s evidentiary weight.

The training asymmetry between stocking and first-line proficiency is a fourth exposure. Texas’s mandate pairs stocking with device-specific training, not with first-line proficiency. Dunne’s named corrective — first-line proficiency as a precondition for device deployment — addresses the asymmetry by aligning device deployment with the proficiency he identifies as foundational.

The legislative off-ramp exists in pieces: New York City’s conditional implementation, the pushback from state health departments, emergency responders, and teachers unions, and a requirement that bills be revisited on a fixed schedule tied to guideline status. A sunset-and-review clause keyed to AHA/Red Cross action would consolidate those mitigations.

The unstated policy assumption is that a second-line device can be deployed in schools without displacing or degrading first-line technique, and that “second-line” status will hold in practice. Understated in the policy’s framing is the cost of first-line training.

Three causal chains

Three causal chains operate together.

Chain one — regulatory pathway as legal trigger. State legislatures have historically keyed medical-device mandates to FDA clearance because that is the available legal signal. The AHA/Red Cross guideline process runs on a slower cycle and produces recommendations rather than clearances. The March FDA authorization immediately made the legislative pathway available; bills in Texas, New York City, and nine other states reference stocking rather than guideline endorsement. This chain explains why the rollout proceeded without waiting for guideline review.

Chain two — marketing-led public demand. Public salience of child choking incidents creates political demand for visible precautions. The company markets directly to police departments, families, and as a baby-shower gift through social media and through Carson as spokesperson, and projects $70 million in global revenue this year. This chain explains the timing of the legislative push: bills track the marketing reach, not the evidence accumulation.

Chain three — training deficit allowing device substitution. Schools have historically provided limited hands-on first-aid training. Stocking a device is faster and more visible than building first-line proficiency. Kenzie Gray’s account, in which in-person training became mandatory only after her son’s death, is consistent with this chain.

The chains are not mutually exclusive. The regulatory pathway supplies the legislative trigger; the marketing reach supplies the political demand; the training deficit supplies the receptive environment. A corrective that addresses only one chain leaves the others intact.

The proximate cause is legislative mandate without guideline endorsement. The sub-cause is that regulatory pathways and clinical guideline processes operate on different evidentiary standards, different review timelines, and different decision criteria, and the two systems are not coordinated. Removing the surface symptom — device stocking without endorsement — without addressing this divergence would only relocate the gap, since the underlying institutional separation would persist.

Additional considerations

The absence of a national registry of choking events and outcomes prevents independent verification of effectiveness claims. The structure of FDA post-market study requirements generates evidence only after widespread distribution. There is no defined review schedule that would automatically revisit state mandates when guidelines update.

The action crosses domains the legislative debate has not fully framed: the clinical domain generates the recommendation; the legislative domain keys mandates off FDA clearance rather than guideline endorsement; the school-administration domain translates mandates into purchasing decisions; consumer behavior is shaped by direct-to-consumer marketing channels including social-media promotion as a baby-shower gift and the Carson spokesperson arrangement.

Two residual uncertainties remain explicit. The year of FDA authorization is not specified in the Journal’s reporting — the article is dated 2026-09-09 and refers to authorization “in March” without a year, and external verification did not resolve whether the authorization was March 2026 or another year. Texas’s mandate pairing is described in the public discussion as “stocking with device-specific training, not with first-line proficiency”; the public record confirms device-specific training is paired with stocking but does not directly confirm first-line proficiency is absent. The inference rests on Dunne’s generalized statement about first-line training gaps and Kenzie Gray’s account that in-person training became mandatory only after her son’s death.

Until the regulatory and clinical tracks converge, state mandates, device donations, and FDA authorization will continue to operate on parallel tracks, and the children, school staff, and families at the center of the policy will continue to navigate a gap the present artifact does not resolve.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Consequences & Sequels
Plays a decision forward to its first- and second-order consequences.
Red-Team Assessment
Models a capable adversary probing a plan for the seams they would exploit.
Root-Cause Analysis
Traces a symptom back along its causal chain to the conditions that actually generated it.